| | Author | Dose/schedule | Clinical setting PFI (mts) | No. pts | RR (%) | PFS (median) (mts) |
| |
Muggia et al. [25] |
50 mg/m2, q21 | ≤6 | 35 | 25.7 | 5.7 | | Gordon et al. [18] | 50 mg/m2, q21 | ALL | 89 | 16.8 | 4.8 | |
Rose et al. [26] | 50 mg/m2, q28 | ≤6 | 37 | 13.5 | 4.0 | | 40 mg/m2, q28 | | | 7.7 | 4.0 | | Katsumata et al. [28] | 50 mg/m2, q28 | ≤6 | 63 | 20.9 | 5.6 | | Markman et al. [31] | 40 mg/m2, q28 | ≤6 | 44 | 9.1 | — | | | | ALL | | 13.5 | 7.2 | | Lorusso et al. [35] | 35 mg/m2, q21 | ≤6 | 17 | 18.9 | — | | | | ≥6 | 20 | 10.0 | — | | Sehouli et al. [36] | 20 mg/m2, q15 | ALL | 64 | 10.9 | 4.3 | | Du Bois et al. [37] | PLD (40 mg/m2) d1
CBDCA (AUC 6) d1, q28 | ≥6 | 67 | 68 | 11.6 | | Rapoport et al. [38] | PLD (50 mg/m2) d1
CBDCA (AUC 5) d1, q28 | ALL
7–12 | 40
19 | 67.5
52.6 | 11.9
9.7 | | Ferrero et al. [39] | PLD (30 mg/m2) d1
CBDCA (AUC 5) d1, q28 | ALL
7–12
≥12 | 96
43
53 | 62.5
—
— | 9.4
7.9
11.4 | | Nicoletto et al. [40] | PLD (30 mg/m2) d1
OXA (70 mg/m2) d1, q28 | ≤6
≥6 | 14
29 | 28.6
66.7 | 5.9
9.9 | | D’Agostino et al. [41] | PLD (30 mg/m2), d1
GEM (1000 mg/m2), d1, 8 q21 | ≤12
≥12 | 36
31 | 25.0
45.2 | —
— | | Ferrandina et al. [42] | PLD (30 mg/m2), d1
GEM (1000 mg/m2), d1, 8 q21 | RES
≥12 | 66
45 | 21.6
53.7 | 5
8.7 | Verhaar-
Langereis et al. [43] | PLD (30 mg/m2) d1/TPT (1.0 mg/m2) d1–5 q21 and PLD (40 mg/m2), d1 TPT (0.75 mg/m2), d1–5 q21 | ≤12 | 27 | 28.0 | 7.5 | | Campos et al. [44] | PLD (30 mg/m2), d1, q21 PTX (70 mg/m2), weekly | ALL
≤12
≥12 | 37
24
13 | 29.0
17.0
54.0 | —
| | Katsaros et al. [45] | PLD (30 mg/m2), d1
vinorelbine (30 mg/m2), d1, q21 | ALL | 30 | 37.0 | 5.5 | | Joly et al. [46] | PLD (40 mg/m2), d1
ifosfamide (1700 mg/m2), d1–3 q28 | ALL
RES
SEN | 98
57
41 | 28.0
19.0
41.0 | —
|
|
|
